# Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

> **NCT04315233** · PHASE1 · RECRUITING · sponsor: **University of Utah** · enrollment: 34 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- Recurrent Ovarian Carcinoma

## Interventions

- **DRUG:** Ribociclib
- **DRUG:** Belinostat

## Key facts

- **NCT ID:** NCT04315233
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-05-03
- **Primary completion:** 2025-06
- **Final completion:** 2026-08
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2025-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04315233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04315233, "Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04315233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*